Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects

• Status: Completed
• Trial end date: 2018-02-20
• Target enrollment: 0
• Participant gender: Male

Summary

This trial is looking at whether the LEO 90100 foam causes irritation of the skin in healthy Japanese male adults without psoriasis. A single application of LEO 90100 foam and its vehicle will each be made to 2 body sites in 20 subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: LEO Pharma
• Treatments: Betamethasone; Betamethasone benzoate; Betamethasone sodium phosphate; Betamethasone Valerate; Betamethasone-17,21-dipropionate; Calcipotriene

Criteria

Key Inclusion Criteria:

• Signed informed consent has been obtained.

• Healthy Japanese male subjects.

• Aged 20 to 40 years inclusive.

Key Exclusion Criteria:

• Body Mass Index outside the range 18-25 kg/m²

• Use of any medication (systemic or topical) within 2 weeks of Day 1.